Cargando…

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience

Background: Primary central nervous system lymphoma (PCNSL) is a lymphoma whose primary lesion is localized in the brain and spinal cord. Treatment is a combination of high-dose methotrexate-based chemotherapy and whole-brain irradiation, often leading to recurrence. Pathologically, non-GCB type dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuura, Jin, Kuroda, Jun-Ichiro, Takezaki, Tatsuya, Shinojima, Naoki, Mukasa, Akitake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648217/ http://dx.doi.org/10.1093/noajnl/vdab159.094

Ejemplares similares

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

MPC-7 Clinical features of Diffuse hemispheric glioma, H3 G34-mutant in children and young adults
por: Takeshima, Yuki, et al.
Publicado: (2021)

IM-8 Significance of IL-1 pathways in Glioblastoma
por: Kai, Keitaro, et al.
Publicado: (2021)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

MLTI-15. A CASE SERIES OF PRE-OPERATIVE GAMMA-KNIFE RADIOSURGERY FOR RESECTABLE BRAIN METASTASES
por: Takezaki, Tatsuya, et al.
Publicado: (2019)

ML-03 RECONSIDERATION OF TREATMENT FOR ELDERLY PATIENTS WITH PRIMARY CENTRAL NERVE SYSTEM LYMPHOMAS
por: Shinojima, Naoki, et al.
Publicado: (2019)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

COT-18 Trends in Primary Brain Tumors in Kumamoto Prefecture with Declining Birthrate and Aging Population - Kumamoto Prefecture Brain Tumor Epidemiological Survey
por: Shinojima, Naoki, et al.
Publicado: (2021)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
por: Yamaguchi, Takashi, et al.
Publicado: (2020)

ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
por: Furuse, Motomasa, et al.
Publicado: (2020)

MPC-16 RAPID PROGRESSIVE SPINAL DIFFUSE MIDLINE GLIOMA, A CASE REPORT
por: Takezaki, Tatsuya, et al.
Publicado: (2019)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
por: Yoshitake, Hidenobu, et al.
Publicado: (2022)

CS-6 A case of poorly differentiated chordoma with systemic metastasis
por: Shinojima, Naoki, et al.
Publicado: (2021)

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

CBMS-09 Intercellular communication at glioblastoma stem cell niches
por: Hide, Takuichiro, et al.
Publicado: (2020)

BOT-02 2-METHYLTHIO MODIFICATION OF N6-ISOPENTENYLADENOSINE IN MITOCHONDRIAL TRNAS BY CDK5RAP1 PROMOTES THE MAINTENANCE OF GLIOMA-INITIATING CELLS
por: Yamamoto, Takahiro, et al.
Publicado: (2019)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

GCT-36. TREATMENT RESULTS AND RADIATION-INDUCED TUMORS IN CASES OF CENTRAL NERVOUS SYSTEM GERM CELL TUMOR: A LONG-TERM FOLLOW-UP STUDY IN KUMAMOTO PREFECTURE
por: Yamamoto, Takahiro, et al.
Publicado: (2020)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
por: Hashiba, Tetsuo, et al.
Publicado: (2022)

ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution
por: Kuwahara, Kiyonori, et al.
Publicado: (2020)

CS-03 LARGE CYSTIC INTRADURAL SCHWANNOMA IN CERVICAL REGION: A CASE REPORT
por: Takeshima, Yuki, et al.
Publicado: (2019)

CS-07 A CYSTIC LONG-SEGMENT CERVICAL SCHWANNOMA: A CASE REPORT
por: Takeshima, Yuki, et al.
Publicado: (2019)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

EPEN-02. EVALUATION OF TREATMENT OUTCOMES AND EXPRESSION OF EMT-RELATED TRANSCRIPTION FACTORS AS NOVEL THERAPEUTIC TARGETS IN PEDIATRIC EPENDYMOMA
por: Makino, Keishi, et al.
Publicado: (2020)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
por: Otani, Ryohei, et al.
Publicado: (2020)

2-Methylthio Conversion of N6-Isopentenyladenosine in Mitochondrial tRNAs by CDK5RAP1 Promotes the Maintenance of Glioma-Initiating Cells
por: Yamamoto, Takahiro, et al.
Publicado: (2019)

Atypical pituitary abscess lacking rim enhancement and diffusion restriction with an unusual organism, Moraxella catarrhalis: A case report and review of the literature
por: Kawano, Tatsuya, et al.
Publicado: (2021)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

ML-01 Pathological characteristics of primary central nervous system lymphoma with atypical radiological finding
por: Inukai, Madoka, et al.
Publicado: (2020)

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)
por: Soussain, Carole, et al.
Publicado: (2022)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

ML-4 A case of primary CNS lymphoma diagnosed 5 years after stereotactic radiosurgery
por: Tabei, Yusuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d93tl2mkvptt1ue874ut3i5636